Clinical Research Directory

Inclusion Criteria: 1. Pregnant women between 36+5 and 41+5 weeks of gestation 2. Singleton pregnancy 3. Aged 18 years or older 4. Unfavourable cervix (Bishop Score less than or equal to 6) 5. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements. Exclusion Criteria: 1. Breech presentation 2. Early labour 3. Contraindication to vaginal birth (placenta praevia, transverse lie, known or suspected cephalo-pelvic disproportion or other factor contraindicated to vaginal birth in the opinion of the investigator) 4. Fetal growth restriction with oligohydramnios and/or abnormal Dopplers 5. Presence of reduced fetal movements requiring urgent delivery, abnormal CTG or recent antepartum haemorrhage requiring immediate delivery 6. Medical conditions: i. sexually transmitted infections (active infections only) ii. bleeding disorders, on anticoagulants, steroid or aspirin therapy iii. prior uterine operations (Caesarean Section or myomectomy) 7. Contra-indications to mifepristone including chronic adrenal, hepatic, renal failure 8. Hypersensitivity to mifepristone or to any excipients, or malnutrition 9. Severe asthma uncontrolled by therapy and inherited porphyria 10. Any investigational drug with an expected interaction with mifepristone which has been administered within 30 days prior to the trial drug administration.